DKK5.21 -0.2 -3.0%
Last Trade - 3:59pm
Market Cap | £167.6m |
Enterprise Value | £156.3m |
Revenue | £2.71m |
Position in Universe | 759th / 1830 |
Dec 30 (Reuters) - Bioporto A/S BIOPOR.CO : * REG-BIOPORTO ANNOUNCES CE MARK OF NEAR-PATIENT TEST FOR KIDNEY INJURY AND MILESTONES FOR GRAD PLATFORM TECHNOLOGY * OBTAINED CE MARKING IN EU FOR ITS NGALDS, A NOVEL GRAD-BASED TEST FOR NEAR-PATIENT MEASUREMENT OF NGAL, AND ANNOUNCES COMMERCIAL LAUNCH * ITS NOVEL SARS-COV-2 RAPID TEST, ALSO BASED ON GRAD-PLATFORM, IS UNDERGOING CLINICAL TESTING AT UNIVERSITY OF CALIFORNIA, DAVIS Source text for Eikon: ID:nGNE9wLFDc Further company coverage: BIOPOR.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))